Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

601

Shown on this page

Current sort

Stored official records

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Selumetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Anaplastic Astrocytoma, Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Glioblastoma Multiforme, High Grade Glioma, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Interventions: Everolimus, Ribociclib, Temozolomide (TMZ); Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Months to 39 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 11
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Acute Lymphoblastic Leukemia, Pediatric, Obesity, Pediatric
Interventions: Low Glycemic Index Diet; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 5
States / cities: Hartford, Connecticut • Washington D.C., District of Columbia • Buffalo, New York + 2 more

Conditions: Chronic Myelogenous Leukemia (CML) in Blast Crisis, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myelogenous Leukemia (AML), Refractory Biphenotypic Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Relapsed Biphenotypic Leukemia, Relapsed Mixed Lineage Leukemia
Interventions: KPT-330; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Months to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Interventions: Depot medroxyprogesterone acetate (DMPA); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: B Cell Precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 13
States / cities: Clovis, California • Duarte, California • Chicago, Illinois + 10 more

Conditions: Bone Marrow Failure Syndromes
Interventions: MRD-BMT with Fludarabine-based RIC for Acquired AA, MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia, MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 22 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Insufficient Sleep, Obesity
Interventions: Active Parent-Directed Loss-Framed Incentive, Active Supportive Feedback, Digital sleep health messaging with virtual study visit, Digital sleep health messaging without virtual study visit, Fixed sleep goal, Inactive Parent-Directed Loss-Framed Incentive, Inactive Supportive Feedback, Personalized sleep goal; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 12 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19); Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 0 Years to 29 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more

Conditions: Concussion, Intermediate, Concussion, Mild, Concussion, Severe, Mild Traumatic Brain Injury
Interventions: RPM-assisted specialist access; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sepsis
Interventions: personalized dosing adjustment of vancomycin; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Stored official records

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Low GI Diet in Children and Adolescents With ALL

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Fludarabine Based RIC for Bone Marrow Failure Syndromes

Optimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Facilitating Access to Specialty Treatment

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

About this Children's Hospital of Philadelphia institution page